Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): Results From a Double-Blind, Placebo-Controlled, Randomized Withdrawal Study

Endogenous Cushing’s syndrome (CS) is a rare, serious disorder caused by chronic cortisol excess. A phase 3, open-label study (SONICS) demonstrated efficacy and safety of levoketoconazole in adults with CS. LOGICS is a phase 3, double-blind (DB), placebo-controlled, randomized-withdrawal (R-W) study...

Descripción completa

Detalles Bibliográficos
Autores principales: Zacharieva, Sabina, Pivonello, Rosario, Elenkova, Atanaska, Toth, Miklos, Shimon, Ilan, Stigliano, Antonio, Badiu, Corin P, Brue, Thierry Christian, Georgescu, Carmen Emanuela, Tsagarakis, Stylianos, Cohen, Fredric J, Fleseriu, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Neuroendocrinology and Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090707/
http://dx.doi.org/10.1210/jendso/bvab048.1072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090707/
http://dx.doi.org/10.1210/jendso/bvab048.1072

Ejemplares similares